Posted: 05/13/2025 03:47 am
One of the most striking aspects of ORIC's compensation data from recent years pertains to Dr. Jacob M. Chacko, the company's President and Chief Executive Officer. In 2024, Dr. Chacko's total compensation was recorded at $5,282,815¹. Despite a decrease from his 2021 total compensation—which was approximately $6,975,924—his package reflects a substantial investment in leadership during pivotal times. A large component of his 2024 compensation came from option awards, totaling $3,466,878, indicating the company's reliance on long-term incentivization strategies².
In 2023, Dominic Piscitelli, ORIC's Chief Financial Officer, earned $1,449,821 in total compensation³. Unlike Dr. Chacko, Piscitelli's compensation was characterized by more conservative option awards at $651,079, while his base salary remained reasonably robust at $435,584⁴. The compensation differences suggest varied incentivization strategies reflecting the roles' diverse responsibilities.
Remuneration through stock and option awards illustrates ORIC's approach to align executive interests with shareholder value, leveraging compensation to drive long-term performance. The emphasis on option awards, particularly for Dr. Chacko, underscores the company's focus on aligning executive performance with sustained corporate growth, especially as ORIC dedicates resources towards its promising drug, ORIC-944, which has shown encouraging early safety and efficacy data in recent trials⁵.
The pharmaceutical-focused compensation strategy appears effective, as illustrated by the recent trajectory of ORIC's stock price. With a current trading price of $5.41 per share, the stock's year-long market variance, ranging from a low of $3.895 to a high of $14.67, further emphasizes the industry's inherent volatility⁶.
Recent press releases underscore ORIC's strategic developments and growth potentials. The company's operational updates and early-phase results for ORIC-944 suggest robust clinical momentum⁷. As ORIC navigates this intricate dance of clinical advancements and financial strategizing, its approach to executive compensation and focus on therapeutic innovation will likely remain pivotal in its trajectory.
As ORIC Pharmaceuticals continues its quest to develop life-saving treatments, the balance between strategic compensation and operational success presents a template for navigating in today's competitive pharmaceutical landscape.
---
1. "SEC Filing for Dr. Jacob M. Chacko's 2024 Compensation," SEC.gov, accessed May 2025. [Link](https://www.sec.gov/Archives/edgar/data/1796280/000119312525091359/0001193125-25-091359-index.htm)
2. "SEC Filing for Dr. Jacob M. Chacko's 2021 Compensation," SEC.gov, accessed May 2025. [Link](https://www.sec.gov/Archives/edgar/data/1796280/000119312523118496/0001193125-23-118496-index.htm)
3. "SEC Filing for Dominic Piscitelli's 2023 Compensation," SEC.gov, accessed May 2025. [Link](https://www.sec.gov/Archives/edgar/data/1796280/000119312524110069/0001193125-24-110069-index.htm)
4. Ibid.
5. "ORIC Pharmaceuticals Provides Early Phase 1B Data," GlobeNewswire, accessed May 2025. [Link](https://www.globenewswire.com/news-release/2025/01/13/3052803/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html)
6. "ORIC Pharmaceuticals Stock Price Data," accessed May 2025.
7. Ibid; "ORIC Pharmaceuticals Reports Financial Results," GlobeNewswire, accessed May 2025. [Link](https://www.globenewswire.com/news-release/2025/05/05/3074504/0/en/ORIC-Pharmaceuticals-Reports-First-Quarter-2025-Financial-Results-and-Operational-Updates.html)
